Multifocal amelanotic conjunctival melanoma and acquired melanosis sine pigmento

Paridaens, A D; McCartney, A C; Hungerford, J L
March 1992
British Journal of Ophthalmology;Mar1992, Vol. 76 Issue 3, p163
Academic Journal
No abstract available.


Related Articles

  • Amelanotic corneally displaced malignant conjunctival melanoma: a case report evaluated with impression cytology. DE NADAI BARROS, JEISON; MOTONO, MÁRCIA; COSTA, FELIPE D'ALMEIDA; DA CUNHA, MARCELO CARVALHO; CHOJNIAK, MARTHA MOTONO // Arquivos Brasileiros de Oftalmologia;Jan/Feb2014, Vol. 77 Issue 1, p57 

    Here we describe the case of a 65-year-old Caucasian female who presented with an amelanotic malignant conjunctival melanoma and highlight the clinical and pathological features of this rare entity that displayed exclusive corneal invasive growth without evidence of conjunctival tumors other...

  • How to Manage Melanosis. Quinn, Christopher J. // Review of Optometry;8/15/2000 Part 1 of 2, Vol. 137 Issue 8, p113 

    Focuses on the diagnosis of melanosis in the United States. Case of 34-year-old white male with an area of pigmentation over the sclera in the right eye; Types of pigmented conjunctival lesions in general; Oculodermal melanosis; Conjunctival nevi; Primary acquired melanosis; Conjunctival melanomas.

  • Prophylaxis key in managing conjunctival melanoma. Guttman, Cheryl // Ophthalmology Times;06/01/97, Vol. 22 Issue 11, p23 

    Reports that prevention through the detection and management of high-risk precursor lesions is the best treatment for conjunctival melanoma. Characteristics of conjunctival melanoma; Recommendations for the biopsy of lesions exceeding 10 millimeters in diameter; Topical chemotherapy to treat...

  • Incidence of Melanocytic Lesions of the Conjunctiva in a Review of 10 675 Ophthalmic Specimens. Novais, Gustavo A.; Fernandes, Bruno F.; Belfort, Rubens N.; Castiglione, Enzo; Cheema, Devinder P.; Burnier Jr., Miguel N. // International Journal of Surgical Pathology;Feb2010, Vol. 18 Issue 1, p60 

    During the study period, 10 675 human ophthalmic specimens were received at The Henry C. Witelson Ophthalmic Pathology Laboratory and Registry, McGill University, Montreal, Canada. Of those, 271 were conjunctival lesions (2.5%), with 101 being classified as melanocytic: 50 (49.5%) nevi, 36...

  • Melanoma maligno conjuntival. NOVAIS, GUSTAVO AMORIM; KARP, CAROL LYNN // Arquivos Brasileiros de Oftalmologia;2012, Vol. 75 Issue 4, p289 

    Introduction: Melanocytic tumors comprise a wide range of lesions. These lesions can be nevi, primary acquired melanosis with or without atypia or malignant as conjunctival melanoma. Early recognition of the clinical features allows precise diagnosis and adequate intervention, reducing the rates...

  • CITATIONS AND CLINICIANS' NOTES: ONCOLOGY AND PATHOLOGY.  // Current Medical Literature: Ophthalmology;2005, Vol. 15 Issue 3, p69 

    Presents citations and clinicians' notes relating to oncological and pathological studies. "The Treatment of Primary Acquired Melanosis (PAM) With Atypia by topical Mitomycin C," by J. Pe'er and J. Frucht-Pery; "Conjunctival Melanoma in the Netherlands: A Nationwide Study," by G. S. Missotten,...

  • Progression of Conjunctival Primary Acquired Melanosis (PAM) to Widely Spreaded Malignant Melanoma. Jandroković, Sonja; Popović-Suić, Smiljka; Mandić, Jelena Juri; Kuzman, Tomislav // Collegium Antropologicum;2014, Vol. 38 Issue 4, p1187 

    Primary acquired melanosis (PAM) is an acquired pigmentation of the conjunctival epithelium, a preinvasive pigmented lesion. When it is associated with cellular atypia it can lead to the developement of melanoma. We report a case report of malignant melanoma of the conjuntiva, which arrised from...

  • Chemotherapy in eye cancer. Dolland, R. // CME: Continuing Medical Education;Apr2013, Vol. 31 Issue 4, p138 

    The article presents guidelines for chemotherapy in eye cancer. Chemotherapeutic agents could be classified as DNA damaging and DNA repair inhibitors. Basal cell carcinoma, malignant melanoma, squamous cell carcinoma (SCC), sebaceous gland carcinoma and Merkel cell carcinoma are malignant...

  • Immunophenotypic markers to differentiate between benign and malignant melanocytic lesions. Keijser, S.; Missotten, G. S.; Bonfrer, J. M.; de Woiff-Rouendaal, D.; Jager, M. J.; de Keizer, R. J. W. // British Journal of Ophthalmology;Feb2006, Vol. 90 Issue 2, p213 

    Background/aims: The authors investigated the expression of S100A1, S100A6, S100B, MelanA, and CEA in conjunctival naevi, primary acquired melanosis (PAM), conjunctival melanoma, and uveal melanoma in order to assess their potential usefulness in the pathological differential diagnosis of these...

  • Epistaxis or epiphora as a sign for extension of a conjunctival melanoma. A series of six patients with nasolacrimal recurrence. G S Missotten // British Journal of Ophthalmology;Oct2010, Vol. 94 Issue 10, p1328 

    PURPOSE: To characterise malignant conjunctival melanomas with extension and recurrence in the nasolacrimal system. METHODS: Localisation of the primary tumour and recurrences of 210 conjunctival melanomas treated in The Netherlands were reviewed for orbital and nasal tumours (1978–2008)....


Read the Article


Sign out of this library

Other Topics